Wolfe Research upgrades Biogen and AbbVie to Outperform, setting $300 targets based on pipeline strength, patent extensions, and solid earnings performance. The post Biogen (BIIB) and AbbVie (ABBV) Receive Rare Double Upgrades: What Investors Need to Know appeared first on Blocko...